Bone marrow aluminium storage in renal failure

Oral aluminum administration to rats wih normal renal function. 1. Impairment of erythropoiesis

Aluminum (Al) toxicity has been mainly investigated in uremic patients although healthy subjects and patients without renal insufficiency are not exempt from its potential deleterious effects. This experimental study aims to elucidate the action of different doses of Al citrate on in vivo erythropoiesis and find out whether the metal exerts a local toxic effect upon the bone marrow late erythroid progenitor cells. The groups in the first experimental series were: C1 (n=5) controls and TAl-1 (n=5) rats receiving 1 micromol Al citrate/g body weight/day by gavage. Colony-forming units-erythroid (CFU-E) development was inhibited in the TAl-1 group, but the median osmotic fragility (MOF) and hematocrit (Ht) values were similar to those of the C1 group. The groups in the second series were C2 (n=5) controls and TAl-2 (n=5) rats receiving Al citrate in drinking water (100 mmol/l). The TAl-2 group showed decreased Ht, hemoglobin concentration, MOF and red blood-cell life-span values (P<0.05), and a marked inhibition of the CFU-E development (P<0.01). Serum and bone Al concentrations were increased in both Al-treated groups (P < 0.01). There was a dose-dependent increase in bone Al levels (P < 0.01) and a dose-dependent decrease of CFU-E development (P<0.05). The CFU-E development was inversely correlated with the bone Al content (r=-0.79; P<0.05). The results demonstrate that even very low doses of Al citrate impair erythropoiesis in vivo and higher doses exert a deleterious action on both CFU-E and mature erythrocytes. This might show a local effect of Al on CFU-E caused by the bone sensitivity to the metal accumulation.

Hematological effects of aluminum on living organisms

1. Aluminum has been of great interest for many researchers over a number of years; its biochemical and physiological role is not yet fully clear. There are few papers describing the hematological consequences of its excess in living organisms and most of their data are cited in this paper. 2. Aluminum reduced the deformability of erythrocytes, and such cells are rather frequently retained in the reticuloendothelial system of the spleen and eliminated faster from the blood stream. 3. Aluminum produces peroxidative changes in the erythrocytes membrane, leading to hemolysis. Therefore, the depressed erythrocyte count in animals intoxicated with aluminum may be the consequence of both the hemolytic action of aluminum and the shortened time of survival of erythrocytes. 4. It was demonstrated that aluminum inhibits heme biosynthesis in vitro. This problem requires, however, further studies and observation. 5. Changes occurring under the influence of Al3+ on the leukocyte system of animals suggest the influence of this element on the resistance of the organism, but the mechanism of the action of Al3+ still requires elucidation. 6. Cell metabolism including blood cells may be affected by aluminum in many ways, the more so as the element may combine in vitro with amino acids, peptides, proteins, enzymes, substrates, cofactors, nucleotides and carbohydrates. Aluminum stimulates NADPH oxidation and takes part in the process of free radical formation.

Staining of bone for aluminum: use of acid solochrome azurine

Fourteen individuals on long term hemodialysis, with varying amounts of aluminum in bone from 11 to 296 mg/kg by flameless atomic absorption spectrophotometry, were examined to see whether the aluminon or acid solochrome azurine (ASA) staining reactions best approximated the chemical determination. Correlation coefficients were 0.78 for aluminon and 0.88 for ASA. Together with 11 additional patients morphometric parameters were compared with the two aluminum stains. The aluminon stain gave satisfactory results in the osteomalacic group but underestimated the amount of aluminum present in those with hyperparathyroid, mixed or aplastic disease. Some individuals showed a striking difference between the two techniques which could have led to an erroneous conclusion regarding the amount of aluminum present. The aluminon stain was pH dependent and together with ASA could be enhanced by prior heat treatment of the sections. It is recommended that ASA either replace aluminon for routine use or be used together with the aluminon stain, particularly for bones without osteomalacia or with mild to moderate aluminum storage.

[Aluminum toxicity]

In view of the increasing pollution of our environment and forest decline, growing interest has been focused on aluminum toxicity. Aluminum is one of the most abundant metals and commonly present in tap water, beverages, food, cosmetics, and pharmaceutical preparations. Thus everybody is exposed to aluminum to a greater or lesser extent. It is now beyond any doubt that aluminum intoxication may cause encephalopathy, fracturing vitamin D resistant osteomalacia, and microcytic anemia in patients with chronic renal insufficiency as well as in experimental animals. The risk of aluminum intoxication has also to be considered in several other groups. These include elderly individuals with physiologically impaired excretory renal function who are treated with aluminum-containing antacids, patients with chronic liver disease, infants who are fed highly aluminum-contaminated formula at a time when their excretory renal function has not jet fully developed, patients on total parenteral nutrition, and, possibly, patients with Alzheimer's disease.

Aluminum and chronic renal failure: sources, absorption, transport, and toxicity

In normal subjects the gastrointestinal tract is a relatively impermeable barrier to aluminum with a low fractional absorption rate for this metal ion. Aluminum absorbed from the gastrointestinal tract is normally excreted by the kidneys; in the presence of impaired renal function aluminum is retained and accumulates in body tissues. Aluminum-containing medications are given, by mouth, to patients with chronic renal failure as phosphate-binding agents for the therapeutic control of hyperphosphatemia. Patients with chronic renal failure are also exposed to aluminum in domestic tap-water supplies used either for drinking or, in those on dialysis treatment, in the preparation of their dialysate. In patients with end-stage chronic renal failure, particularly in those on treatment by hemodialysis, the accumulation of aluminum in bone, brain, and other tissues is associated with toxic sequelae. An increased brain content of aluminum appears to be the major etiological factor in the development of a neurological syndrome called either "dialysis encephalopathy" or "dialysis dementia"; an increased bone content causes a specific form of osteomalacia. An excess of aluminum also appears to be an etiological factor in a microcytic, hypochromic anemia that occurs in some patients with chronic renal failure on long-term treatment with hemodialysis. The various mechanisms involved in the toxic phenomena associated with the accumulation of aluminum in body tissues have not been clearly defined but are the subject of extensive investigations.

Aluminum inhibits erythropoiesis in vitro

Anemia has been associated with aluminum intoxication in patients on chronic dialysis and in animals. In studies presented here, in vitro human erythroid culture was used to delineate the effects of aluminum on normal hematopoiesis. Aluminum by itself in routine culture, even at very high levels (1,035 ng/ml), did not significantly affect erythroid colony growth. The addition of human transferrin to the culture, however, resulted in a marked dose-dependent inhibition of erythroid, but not myeloid colony growth. At all doses, CFU-E progenitors showed greater inhibition than burst-forming units (BFU-E). Aluminum inhibition was not overcome by increasing the dose of erythropoietin or adding additional burst-promoting activity to the culture. Inhibition by aluminum was directly related to the number of binding sites on transferrin in the culture, and was not observed in the presence of fully iron-saturated transferrin.

Laser microprobe mass analysis (LAMMA) to verify the aluminon staining of bone

Triammonium aurin tricarboxylate (aluminon) has been used to localize aluminum in 2 micron sections of undecalcified, methyl methacrylate embedded bone obtained from patients with terminal chronic renal failure. Aluminum appeared in four cases as bright red lines at the mineralized-bone boundary. In two cases, however, purplish lines were found and one patient showed red as well as purplish lines. Laser microprobe mass analysis (LAMMA) identified aluminum at the location of the red lines and both aluminum and iron at the purplish lines. Furthermore, both iron and aluminum were found in histiocytic bone marrow cells, which showed brownish aluminon staining. It appears that when aluminum and iron occur together, aluminon staining may yield aberrant results. This study shows that LAMMA can be used for the identification of elements sought by histochemical methods and thus permits the evaluation of their staining effects.

When is it an osteoclast?

Using acid phosphatase as a marker, osteoclasts were examined from single sections of undemineralised iliac crest biopsies from patients with renal failure and from normal controls. Eighty one per cent of the cells from controls and 56% of the cells from patients with renal failure appeared to be non-nucleated or mononucleated. Serial sections showed, however, that 73% of the control cells were actually multinucleated as were 91% of the patients' cells. Howship's lacunae were present in similar proportions in the controls whether the cells were multinucleated or not, suggesting that they should all be classed as osteoclasts. More multinucleated cells and lacunae were present in the patients with renal failure. It is concluded that all acid phosphatase cells adjacent to bone are osteoclasts and that the presence of more lacunae and multinucleated cells in renal failure is compatible with enhanced cellular resorption.